Clinical Evaluation of the Synergistic Efficacy of Electroacupuncture Intervention in Immunotherapy for Advanced NSCLC

INTERVENTION: Acupuncture group:Conventional immunotherapy combined with acupuncture intervention;Sham acupuncture group:Conventional immunotherapy; CONDITION: lung cancer PRIMARY OUTCOME: Progression‐free survival; SECONDARY OUTCOME: Objective response rate;Overall survival;European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30;Lymphocyte subsets; INCLUSION CRITERIA: 1. Aged 18–75 years, regardless of sex; 2. Histologically or cytologically confirmed advanced non‐squamous non‐small cell lung cancer (NSCLC); 3. Clinical stage IIIB/IIIC disease unsuitable for curative treatment, stage IV disease, or recurrent/metastatic NSCLC; 4. Scheduled to receive a standardized PD‐1 inhibitor‐based combination therapy regimen; 5. At least one measurable lesion according to RECIST version 1.1; 6. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0–1; 7. Estimated life expectancy of >=3 months; 8. Adequate major organ function and ability to tolerate the study treatment and follow‐up; 9. Voluntary participation in this study with written informed consent.